Carolyn Schooley
Adult Health · Casa Grande, AZNPI 1083844757
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 40.1% of the total. Reporting peaked in 2021 at $1,142 and has fallen 82.3% since, to $202 in 2025.
Across 186 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$335
- Sunovion Pharmaceuticals Inc.$250
- Amgen$224
- AstraZeneca$178
- Lilly USA, LLC$134
- plus $919 from 23 others
What the payments were for
- Food & beverage$3,27896%
- Education$1284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $1,365 |
| Astellas Pharma US Inc | 8 | $335 |
| Sunovion Pharmaceuticals Inc. | 12 | $250 |
| Amgen | 13 | $224 |
| AstraZeneca | 4 | $178 |
| Lilly USA, LLC | 8 | $134 |
| GSK | 7 | $117 |
| Novartis | 5 | $112 |
| Abbott | 5 | $74 |
| Novo Nordisk | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Grifols USA, LLC | 3 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Amarin Pharma, Inc. | 3 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Bayer | 3 | $38 |
| Mylan Specialty L.p. | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Cranial Technologies, Inc | 1 | $14 |
| Merck | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Lucid Diagnostics Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$122
How this compares
$3,406 in reported general payments places this provider in the 85th percentile of 314 adult health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $148,051 |
| TrulicityDulaglutide | 34 | $76,380 |
| EliquisApixaban | 23 | $34,117 |
| XareltoRivaroxaban | 37 | $31,995 |
| MounjaroTirzepatide | 20 | $28,246 |
| VraylarCariprazine Hcl | 14 | $23,509 |
| JardianceEmpagliflozin | 17 | $20,925 |
| RybelsusSemaglutide | 11 | $20,424 |
| FarxigaDapagliflozin Propanediol | 21 | $17,277 |
| MyrbetriqMirabegron | 21 | $16,896 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $14,669 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $13,526 |
| GemtesaVibegron | 17 | $12,845 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $11,643 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $10,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $70 | $168,475122 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $134 | $104,62654 claims |
| PfizerEliquis | $12 | $34,11723 claims |
| Johnson & JohnsonXarelto | $31 | $31,99537 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $178 | $31,94642 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $17 | $27,46429 claims |
| AbbVieVraylar, Synthroid | $1,365 | $25,30941 claims |
| Astellas Pharma US IncMyrbetriq | $335 | $16,89621 claims |
| GSKAnoro Ellipta | $117 | $13,52616 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $12,84517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 314 adult health providers in Arizona.
Other adult health in Casa Grande
- Therese SargentPhoenix$307K
- Heather McCoyScottsdale$156K
- Jennifer MylodGlendale$131K
- Natalie WilsonPhoenix$94K
- Amy KleinhansMesa$60K
- Michelle TaylorGilbert$36K
- Sherry DentonScottsdale$23K
- Kristin StaniszewskiPhoenix$15K
- Stacey GourdouxPhoenix$15K
- Patricia MaybornePhoenix$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.